U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07773623) titled 'An Interventional Study of Upadacitinib Extended-Release Tablets in Patients With Refractory Uveitis' on July 29.
Brief Summary: Upadacitinib sustained-release tablets have not yet been approved for the treatment of uveitis. The current use falls under the category of "off-label medication", which means providing patients with potentially beneficial treatment options in the absence of formal approval. Based on existing case reports and mechanism studies, we believe that upadacitinib sustained-release tablets have potential therapeutic value for patients with uveitis who have not responded well to traditional treatment regimens or th...